BC Week In Review | Dec 22, 2014
Clinical News

Onexton Gel clindamycin phosphate/benzoyl peroxide regulatory update

FDA approved Onexton Gel clindamycin phosphate/benzoyl peroxide from Valeant to treat acne vulgaris in patients ages =12 years. Valeant said it plans to launch the fixed combination of 1.2% clindamycin phosphate and 3.75% benzoyl peroxide...
BC Week In Review | Oct 6, 2014
Company News

Lumara Health, AMAG Pharmaceuticals deal

AMAG will acquire Lumara's maternal health business in a cash and stock deal. Lumara (formerly KV Pharmaceutical Co. ) will receive $600 million in cash and 3.2 million AMAG shares worth about $74.4 million based on...
BC Week In Review | Oct 6, 2014
Company News

Lumara Health, Perrigo deal

Perrigo will acquire Lumara's OTC women's healthcare business for $82 million in cash. Perrigo will gain Lumara's Clindesse clindamycin phosphate and Gynazole-1 butoconazole nitrate vaginal creams and Evamist estradiol transdermal spray. Perrigo said it plans...
BC Extra | Sep 30, 2014
Company News

AMAG gains on M&A deal to add Makena

AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) jumped $6.54 (28%) to $29.72 Monday on news it agreed to acquire the maternal health business of Lumara Health Inc. (Chesterfield, Mo.) -- once known as KV Pharmaceutical Co. -- for...
BC Week In Review | Nov 4, 2013
Company News

Galderma, PreCision Dermatology sales and marketing update

PreCision's Onset Dermatologics LLC subsidiary acquired worldwide rights to acne drug Clindagel 1% clindamycin from Galderma's Galderma Laboratories L.P. unit for an undisclosed amount. The product is a topical formulation of clindamycin phosphate. Clindagel will...
BC Week In Review | Mar 16, 2009
Company News

Valeant sales and marketing update

Valeant's Coria Laboratories Ltd. unit launched Acanya clindamycin/benzoyl peroxide in the U.S. to treat acne vulgaris in patients 12 years and older. The price is not disclosed. The combination of clindamycin phosphate 1.2% and benzoyl...
BC Week In Review | Oct 27, 2008
Clinical News

Acanya gel regulatory update

FDA approved an NDA from Dow for topical Acanya gel to treat acne vulgaris in patients 12 years and older. Acanya is a combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% in a gel....
BC Week In Review | Nov 13, 2006
Clinical News

Ziana Gel regulatory update

FDA approved the companies' NDA for Ziana Gel to treat acne vulgaris in patients 12 years and older. The drug contains clindamycin phosphate 1.2% and tretinoin 0.025%. Dow Pharmaceutical Sciences , Petaluma, Calif.   Medicis Pharmaceutical...
BC Week In Review | Jan 3, 2005
Clinical News

Clindamax clindamycin phosphate regulatory update

FDA approved Clindamax 2% clindamycin phosphate vaginal cream for 3 or 7 day treatment of bacterial vaginosis (BV). PharmaDerm , Atlanta, Ga.   Product: Clindamax clindamycin phosphate   Business: Infectious  ...
BC Week In Review | Dec 6, 2004
Clinical News

Clindesse clindamycin phosphate regulatory update

FDA approved an NDA for Clindesse 2% single-dose vaginal cream therapy to treat bacterial vaginosis. KV Pharmaceutical Company (KVA), St. Louis, Mo.   Product: Clindesse clindamycin phosphate   Business: Infectious  ...
Items per page:
1 - 10 of 12